Über uns
Firmenpräsentation
Milestones
Presse
Forschung & Entwicklung
5-Aminolävulinsäure
Therapiebereiche
Aktinische Keratose
Glioblastoma
Produkte
Karriere
Kontakt
Consulting
IT Strategie
IT Security & Compliance
IT Ablauf - Aufbau Orga
IT Architekt - Design - Integration
Quick Check Analysen
Digitalisierung - Automatisierung
Business Continuity Planning
Business Projekts
Business Processes
New Office Works - Home Office
Compliance
IT Sicherheitshandbuch
IT Security Organisation
IT Security Check
Notfallhandbuch
Business Continuity Planning
Change & Risk Processes
IT System Validierung
Services
Managed Services
Private Cloud Hosting
VOIP/Callcenter
Colocation
Cloud Backup
Public Cloud MS 365
Virtueller Arbeitsplatz
Pharma & Health Compliance
IT Sourcing - Hybrid Teams
Marketing
Grafik Design
Web Design
Online Marketing Strategie
Shopify Creation
Social Media Campain
Insight
Über uns
Buchungsoptionen
Projektreferenzen
Qualität Compliance
Kundenreferenz
MORE SERVICES
Kontakt
Termin
News Archiv
First-in-Human Study for New Application of Photodynamic Therapy with 5-Aminolevulinic Acid for Extracorporeal Photopheresis
First Patient Enrolled in Phase 2 Trial with Interstitial Photodynamic Therapy
Brustkrebsoperionen mit 5-ALA, Artikel aus Pinneberger Tageblatt
Results of Phase II Trial for Breast Cancer Surgery Published in Breast Cancer Research
Pinneberger Pharmafirma arbeitet an Urintest zur Krebsfrüherkennung
First Patient Enrolled in Pivotal Phase 3 Trial for Breast Conserving Surgery
Artikel aus Pinneberger Tageblatt, April 2021:
Pinneberger Pharma-Unternehmen: Medikament gegen Covid verträglich / Wirksamkeit deutet sich an.
photonamic Acquires Majority Stake in FerroSens
Research with 5-ALA phosphate and Sodium Ferrous Citrate in COVID-19 patients
Start of Phase II Clinical Trial using 5-ALA by the University of Oxford and SBI Pharmaceuticals
Medexus Announces Expanded Availability of Gleolan® in Canada
Case Reports on Treatment with 5-ALA Phosphate for Patients with New Coronavirus Infection (COVID-19)
NX DEVELOPMENT CORP. (NXDC) Receives FDA Orphan-Drug Designation for Gleolan®
NX DEVELOPMENT CORP IN THE USA LAUNCHES GLEOLAN™ (AMINOLEVULINIC ACID HCL) MENINGIOMA PHASE III CLINICAL TRIAL
